Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin(Dana-Farber Cancer Institute), Patrick Y. Wen(Dana-Farber Cancer Institute), Steven N. Kalkanis(Henry Ford Health System), Gordon J. Harris(Harvard University Press), Janet Dancey(Ontario Institute for Cancer Research), Martin Bendszus(Heidelberg University), David Schiff(University of Virginia), Hidefumi Aoyama(Hokkaido University of Science), Mark E. Linskey(University of California, Irvine), Eudocia Q. Lee(Brigham and Women's Hospital), David Macdonald(Western University), Minesh P. Mehta(Columbia University), Elisabeth G.E. de Vries(Karolinska University Hospital), Paul D. Brown(Mayo Clinic), Brigitta G. Baumert(Kantonsspital Graubünden), D. Ross Camidge(University of Colorado Denver), Kim Margolin(City Of Hope National Medical Center), F. Stephen Hodi(Harvard University), John H. Suh(Cleveland Clinic), Riccardo Soffietti(Azienda Ospedaliero Universitaria San Giovanni Battista), Laurie E. Gaspar(University of Colorado Cancer Center), Igor J. Barani(University of California, San Francisco), Michael A. Vogelbaum(Moffitt Cancer Center), Martin J. van den Bent(Erasmus MC Cancer Institute), Susan M. Chang(University of San Francisco), Daniel P. Barboriak(Duke University)
Cited by 1,084
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k